학술논문

1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Document Type
Abstract
Source
In Annals of Oncology October 2023 34 Supplement 2:S660-S660
Subject
Language
ISSN
0923-7534